Israel's Teva targets $31 million sales by 2015, with sights on respiratory market

Best described as the world’s largest generic drugmaker, Israel’s Teva Pharmaceutical Industries (Nasdaq: TEVA) is pitching some of its future on the branded sector, saying that its expertise in the respiratory marketplace, combined with the strength of its product pipeline, is expected to contribute approximately $2.4 billion to the company's overall 2015 targets of $31 billion.

Teva yesterday hosted its Respiratory Opportunity Meeting for the financial community in New York, USA, featuring in-depth presentations on its current and future respiratory growth strategy. Teva intends to file 10 products, six of which are new brands, for approval in the USA and Europe by 2015, targeting around $25 billion in brand value, including new combination products. Despite its upbeat comments, Teva’s shares were down 1.4% at $50.67 on the Nasdaq.

Some of these will centrer around Spiromax, Teva's multi-dose dry powder inhaler devise. The company is also expecting to grow Qvar (beclomethasone) inhalation aerosol for the maintenance treatment of asthma "via aggressive market penetration as first line controller" and "maintain market leadership" of its branded asthma inhaler ProAir (albuterol).